These results indicate that Artemether could be a new AMPK/GSK3β(ser9)/Nrf2 activator for the treatment of inflammation and oxidative stress and a potential therapeutic agent for Alzheimer's disease. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.